Disruptive Pharma to explore oral drug development partnerships at BIO-Europe

Disruptive Pharma will attend BIO-Europe 2026 in Cologne on 9–11 November to meet with pharmaceutical and biotechnology companies and explore development collaborations around Formulite®, our clinically evaluated formulation platform for oral small molecules.

BIO-Europe is one of Europe’s leading life science partnering events, bringing together companies from across the industry for one-to-one meetings to explore potential business and development collaborations. At BIO-Europe, we look forward to discussions with potential partners and customers about oral drug development, formulation challenges and how Formulite® can help improve drug product performance, streamline manufacturing and enable the development of more effective and patient-friendly oral medicines.

At Disruptive Pharma, we offer feasibility studies, formulation and process development, and product optimization using Formulite®. We combine our platform with hands-on development expertise to support pharmaceutical and biotechnology companies in developing new and improving existing oral drug products.

Our Commercial Director, Martina Ferneman, will be attending the event to discuss potential projects and how an initial feasibility study or product optimization could provide a starting point for collaboration.

Interested in exploring what Formulite® could enable for your compounds? Connect with us through partneringONE or contact our commercial team.